NCT06698822 2026-04-14
A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
18 trialsNCT05326464 2025-12-15
Tofacitinib in Recurrent GBM Patients
University of Texas Southwestern Medical Center
Phase 3 Active not recruiting
NCT04431895 2025-09-16
Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study
Huashan Hospital
Phase EARLY_PHASE1 Completed
NCT03976245 2024-11-29
Advanced Therapeutics in Rheumatoid Arthritis (RA)
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 4 Recruiting
NCT05348213 2024-10-23
R-ICE+X
Ruijin Hospital
Phase 2 Recruiting
NCT04721821 2024-04-12
Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.
Pfizer
Completed
NCT04034238 2023-08-01
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT04798287 2022-06-22
STAR-RA-Cancer
Brigham and Women's Hospital
Completed
NCT02092467 2021-08-17
Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
Pfizer
Phase 4 Completed
NCT01815424 2019-04-16
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT01186744 2018-12-26
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT01241591 2018-12-26
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT00960440 2018-12-19
Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors
Pfizer
Phase 3 Completed
NCT03598959 2018-07-26
Tofacitinib Combined With Chidamide in R/R ENKTCL
Sichuan University
Phase 2 Unknown
NCT01163253 2017-06-26
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Terminated
NCT01519089 2015-08-13
A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis
Pfizer
Phase 3 Completed
NCT01276639 2014-09-19
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed
NCT01309737 2014-09-19
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
Pfizer
Phase 3 Completed